BRPI1011993A2 - inibidores de replicação do vírus influenza, seu uso, método de preparação dos mesmos e compositção farmacêutica que os compreende - Google Patents
inibidores de replicação do vírus influenza, seu uso, método de preparação dos mesmos e compositção farmacêutica que os compreende Download PDFInfo
- Publication number
- BRPI1011993A2 BRPI1011993A2 BRPI1011993-0A BRPI1011993A BRPI1011993A2 BR PI1011993 A2 BRPI1011993 A2 BR PI1011993A2 BR PI1011993 A BRPI1011993 A BR PI1011993A BR PI1011993 A2 BRPI1011993 A2 BR PI1011993A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- independently
- group
- optionally substituted
- halogen
- Prior art date
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 40
- 230000010076 replication Effects 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims description 4
- 239000003112 inhibitor Substances 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 269
- 150000003839 salts Chemical class 0.000 claims abstract description 79
- 206010022000 influenza Diseases 0.000 claims abstract description 64
- 239000012472 biological sample Substances 0.000 claims abstract description 22
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 239000013610 patient sample Substances 0.000 claims abstract description 7
- 239000002671 adjuvant Substances 0.000 claims abstract description 3
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2039
- -1 cyano, hydroxy Chemical group 0.000 claims description 629
- 229910052736 halogen Inorganic materials 0.000 claims description 526
- 125000001424 substituent group Chemical group 0.000 claims description 453
- 125000004043 oxo group Chemical group O=* 0.000 claims description 387
- 150000002367 halogens Chemical class 0.000 claims description 323
- 125000003118 aryl group Chemical group 0.000 claims description 284
- 125000003545 alkoxy group Chemical group 0.000 claims description 273
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 220
- 125000005843 halogen group Chemical group 0.000 claims description 204
- 125000001931 aliphatic group Chemical group 0.000 claims description 104
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 97
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 97
- 125000000623 heterocyclic group Chemical group 0.000 claims description 92
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 91
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 90
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 88
- 229920000180 alkyd Polymers 0.000 claims description 85
- 125000001188 haloalkyl group Chemical group 0.000 claims description 84
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 82
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 81
- 125000002431 aminoalkoxy group Chemical group 0.000 claims description 79
- 125000005159 cyanoalkoxy group Chemical group 0.000 claims description 76
- 125000002837 carbocyclic group Chemical group 0.000 claims description 73
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 70
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 65
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 61
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 57
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 51
- 229910052799 carbon Inorganic materials 0.000 claims description 51
- 125000001072 heteroaryl group Chemical group 0.000 claims description 51
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 47
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 45
- 125000004432 carbon atom Chemical group C* 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 125000004429 atom Chemical group 0.000 claims description 38
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 38
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 31
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 30
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 20
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 17
- 125000001246 bromo group Chemical group Br* 0.000 claims description 16
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 13
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 10
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 6
- 241001644525 Nastus productus Species 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 101100113485 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chs-3 gene Proteins 0.000 claims description 4
- 241000084978 Rena Species 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 4
- 229910014585 C2-Ce Inorganic materials 0.000 claims description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 229940126062 Compound A Drugs 0.000 claims description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 244000201986 Cassia tora Species 0.000 claims 1
- 101150027628 Eloa gene Proteins 0.000 claims 1
- 102100030208 Elongin-A Human genes 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 abstract description 12
- 239000011575 calcium Substances 0.000 description 616
- 241000700605 Viruses Species 0.000 description 30
- 239000003814 drug Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 229940124597 therapeutic agent Drugs 0.000 description 20
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 18
- 150000001721 carbon Chemical group 0.000 description 18
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 13
- 230000000069 prophylactic effect Effects 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 208000037798 influenza B Diseases 0.000 description 10
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000003443 antiviral agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 208000037797 influenza A Diseases 0.000 description 8
- 102000005348 Neuraminidase Human genes 0.000 description 7
- 108010006232 Neuraminidase Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 5
- 101710154606 Hemagglutinin Proteins 0.000 description 5
- 241000712431 Influenza A virus Species 0.000 description 5
- 241000713297 Influenza C virus Species 0.000 description 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 5
- 101710176177 Protein A56 Proteins 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 239000000185 hemagglutinin Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241001331845 Equus asinus x caballus Species 0.000 description 4
- 101000823955 Homo sapiens Serine palmitoyltransferase 1 Proteins 0.000 description 4
- 241000713196 Influenza B virus Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100022068 Serine palmitoyltransferase 1 Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 208000037799 influenza C Diseases 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 241000269350 Anura Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 2
- 101001131276 Homo sapiens Sulfhydryl oxidase 2 Proteins 0.000 description 2
- 241001661732 Isavirus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100037268 Secretoglobin family 3A member 1 Human genes 0.000 description 2
- 102100034359 Sulfhydryl oxidase 2 Human genes 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 240000001068 Thogoto virus Species 0.000 description 2
- 108091034135 Vault RNA Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000011841 epidemiological investigation Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 101150064205 ESR1 gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017918 Gastroenteritis viral Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101100028758 Influenza A virus (strain A/Swine/Wisconsin/1/1967 H1N1) PB1-F2 gene Proteins 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500343 Influenzavirus C Species 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 101150103639 PB1 gene Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 150000001942 cyclopropanes Chemical group 0.000 description 1
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical group C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005881 detosylation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940069417 doxy Drugs 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical group O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000037802 influenza A (H3N2) Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18771309P | 2009-06-17 | 2009-06-17 | |
| US61/187,713 | 2009-06-17 | ||
| US28778109P | 2009-12-18 | 2009-12-18 | |
| US61/287,781 | 2009-12-18 | ||
| PCT/US2010/038988 WO2010148197A1 (en) | 2009-06-17 | 2010-06-17 | Inhibitors of influenza viruses replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011993A2 true BRPI1011993A2 (pt) | 2021-07-06 |
Family
ID=42537408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011993-0A BRPI1011993A2 (pt) | 2009-06-17 | 2010-06-17 | inibidores de replicação do vírus influenza, seu uso, método de preparação dos mesmos e compositção farmacêutica que os compreende |
Country Status (37)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2380795T3 (es) * | 2005-05-20 | 2012-05-18 | Vertex Pharmaceuticals, Inc. | Pirrolopiridinas útiles como inhibidores de proteínas quinasas |
| GEP20207129B (en) | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| CN103492381A (zh) | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | 流感病毒复制的抑制剂 |
| CA2822059A1 (en) * | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| WO2012083122A1 (en) * | 2010-12-16 | 2012-06-21 | Vertex Pharmaceutical Incorporated | Inhibitors of influenza viruses replication |
| DK2729445T3 (en) | 2011-07-04 | 2016-01-18 | Rottapharm Biotech Srl | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS |
| EP2729465A2 (en) * | 2011-07-05 | 2014-05-14 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for producing azaindoles |
| UA118010C2 (uk) * | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| US10323012B2 (en) * | 2012-06-05 | 2019-06-18 | Hong Kong Baptist University | Miliusanes as antiviral agents |
| WO2013184985A1 (en) * | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| KR20220143164A (ko) * | 2012-11-21 | 2022-10-24 | 피티씨 테라퓨틱스, 인크. | 치환된 리버스 피리미딘 ｂｍｉ-1 저해제 |
| MX370588B (es) | 2013-08-30 | 2019-12-16 | Ptc Therapeutics Inc | Inhibidores de la bmi-1 de pirimidina sustituida. |
| US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
| HRP20191525T1 (hr) * | 2013-11-13 | 2019-11-29 | Vertex Pharma | Inhibitori replikacije virusa influence |
| EP3421468B1 (en) | 2013-11-13 | 2020-11-04 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| MX2016006197A (es) * | 2013-11-13 | 2016-08-08 | Vertex Pharma | Formulaciones de compuestos de azaindol. |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| DK3126352T3 (en) | 2014-04-04 | 2019-01-21 | Syros Pharmaceuticals Inc | CYCLINE INDEPENDENT KINASE 7 INHIBITORS (CDK7) |
| JP6577570B2 (ja) | 2014-08-08 | 2019-09-18 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | インフルエンザウイルス感染に使用するためのインドール類 |
| DK3191489T3 (da) | 2014-09-08 | 2021-03-29 | Janssen Sciences Ireland Unlimited Co | Pyrrolopyrimidiner til anvendelse ved influenzavirusinfektion |
| MA40773A (fr) | 2014-10-02 | 2017-08-08 | Vertex Pharma | Variants du virus influenza a |
| MA40772A (fr) | 2014-10-02 | 2017-08-08 | Vertex Pharma | Variants du virus de la grippe a |
| WO2016113277A1 (en) * | 2015-01-16 | 2016-07-21 | Bayer Cropscience Aktiengesellschaft | Method for preparing 4-cyanopiperidine hydrochloride |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| WO2016191079A1 (en) * | 2015-05-26 | 2016-12-01 | Boropharm, Inc. | Improved process for preparing boryl 7-azaindole compounds |
| MA43298A (fr) * | 2015-11-27 | 2021-04-14 | Janssen Sciences Ireland Unlimited Co | Derives heterocycliques d'indole pour des infections par le virus de la influenza |
| EP3362451B1 (en) | 2015-12-09 | 2023-04-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| EA201891576A1 (ru) * | 2016-01-07 | 2018-11-30 | Янссен Сайенсиз Айрлэнд Юси | Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа |
| KR20180100375A (ko) * | 2016-01-20 | 2018-09-10 | 얀센 사이언시즈 아일랜드 유씨 | 인플루엔자 바이러스 감염에서 사용하기 위한 아릴 치환 피리미딘 |
| WO2017133667A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof |
| WO2017198122A1 (zh) * | 2016-05-19 | 2017-11-23 | 四川大学 | 抗流感小分子化合物及其制备方法和用途 |
| WO2018033082A1 (en) * | 2016-08-16 | 2018-02-22 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CN109641868B (zh) | 2016-08-30 | 2021-12-03 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| CN110623958B (zh) | 2016-09-05 | 2022-05-17 | 广东众生睿创生物科技有限公司 | 抗流感病毒嘧啶衍生物 |
| EP3538523B1 (en) * | 2016-11-08 | 2021-05-19 | Cancer Research Technology Limited | Pyrimidinone derivatives as cdc7 inhibitors |
| JP7034162B2 (ja) * | 2016-12-15 | 2022-03-11 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | インフルエンザウイルス複製の阻害剤及びその使用 |
| US11542233B2 (en) * | 2016-12-23 | 2023-01-03 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| WO2018127096A1 (en) | 2017-01-05 | 2018-07-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| CN110446711B (zh) | 2017-03-02 | 2022-02-15 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| EP3609502A1 (en) | 2017-04-12 | 2020-02-19 | Vertex Pharmaceuticals Incorporated | Combination therapies for treating influenza virus infection |
| TWI778052B (zh) * | 2017-04-24 | 2022-09-21 | 美商共結晶製藥公司 | 流感病毒複製之抑制劑 |
| CN108727369B (zh) * | 2017-04-25 | 2023-06-09 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| IL301709B2 (en) | 2017-08-09 | 2025-07-01 | Denali Therapeutics Inc | Compounds, compositions and methods |
| EP3676297B1 (en) | 2017-09-01 | 2023-05-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN109745309B (zh) * | 2017-11-03 | 2022-01-28 | 香港浸会大学 | 作为抗病毒剂的密瘤杀 |
| CN110117285B (zh) * | 2018-02-07 | 2023-02-03 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| KR102484804B1 (ko) * | 2018-03-05 | 2023-01-04 | 광둥 레이노벤트 바이오테크 컴퍼니 리미티드 | 이미다졸계 화합물의 결정 형태, 염 형태 및 그의 제조 방법 |
| US20210147413A1 (en) | 2018-04-06 | 2021-05-20 | Janssen Pharmaceuticals, Inc. | Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate |
| CN110590768B (zh) * | 2018-06-13 | 2021-02-26 | 银杏树药业(苏州)有限公司 | 杂环化合物、其组合物及其作为抗流感病毒药物的应用 |
| EP3829719B1 (en) * | 2018-07-27 | 2025-04-02 | Cocrystal Pharma, Inc. | Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication |
| WO2020055544A2 (en) | 2018-08-17 | 2020-03-19 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| BR112021015639A2 (pt) | 2019-02-13 | 2021-10-05 | Denali Therapeutics Inc. | Compostos, composições e métodos |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US20220177456A1 (en) * | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2020212399A1 (en) | 2019-04-15 | 2020-10-22 | Janssen Pharmaceutica Nv | Method for preparing an alkyl trans-3-aminobicyclo[2.2.2]octane-2-carboxylic acid ester compound |
| WO2020256820A1 (en) | 2019-06-20 | 2020-12-24 | Janssen Pharmaceuticals, Inc. | Formulations of azaindole compounds |
| US12252487B2 (en) | 2019-07-22 | 2025-03-18 | Guangdong Raynovent Biotech Co., Ltd. | Dominant salt forms of pyrimidine derivatives, and crystal forms thereof |
| CN114555595B (zh) * | 2019-08-30 | 2023-12-26 | Tsd生命科学有限公司 | 咪唑并吡啶衍生物及将其作为有效成分的药学组合物 |
| WO2021047437A1 (zh) * | 2019-09-10 | 2021-03-18 | 广东众生睿创生物科技有限公司 | 一种用于治疗病毒性感冒的药物组合物及其制剂 |
| RU2726119C1 (ru) * | 2019-11-22 | 2020-07-09 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Новые производные полиолов, их применение, фармацевтическая композиция на их основе |
| US20230265107A1 (en) | 2020-07-10 | 2023-08-24 | Sichuan Haisco Pharmaceutical Co., Ltd. | Pb2 inhibitor, and preparation method therefor and use thereof |
| CN112979647B (zh) * | 2021-03-12 | 2022-05-20 | 浙江大学 | 含氮杂氨基酸的氮杂吲哚衍生物及制备和应用 |
Family Cites Families (174)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4349552A (en) | 1978-10-30 | 1982-09-14 | Fujisawa Pharmaceutical Company, Ltd. | 5-Fluorouracil derivatives, and their pharmaceutical compositions |
| PT85662B (pt) | 1986-09-10 | 1990-06-29 | Sandoz Sa | Processo para a preparacao de derivados de aza-indol e de indolizina e de composicoes farmaceuticas que os contem |
| WO1990007926A1 (en) | 1989-01-20 | 1990-07-26 | Pfizer Inc. | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
| DE4304455A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| IL129871A (en) | 1994-05-06 | 2003-11-23 | Pharmacia & Upjohn Inc | Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections |
| US6075037A (en) | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5821243A (en) | 1996-07-22 | 1998-10-13 | Viropharma Incorporated | Compounds compositions and methods for treating influenza |
| US6187713B1 (en) | 1996-10-31 | 2001-02-13 | Corning Incorporated | Method of making activated carbon bodies having improved adsorption properties |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| CN1166636C (zh) | 1999-01-07 | 2004-09-15 | 惠氏 | 用于治疗抑郁症的芳基哌嗪基-环己基吲哚衍生物 |
| AU2494300A (en) | 1999-01-07 | 2000-07-24 | American Home Products Corporation | 3,4-dihydro-2h-benzo(1,4)oxazine derivatives |
| US6313126B1 (en) | 1999-01-07 | 2001-11-06 | American Home Products Corp | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
| US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
| AR028475A1 (es) | 1999-04-22 | 2003-05-14 | Wyeth Corp | Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion. |
| US20030153560A1 (en) | 1999-04-23 | 2003-08-14 | Salituro Francesco G. | Inhibitors of c-Jun N-terminal kinases (JNK) |
| EP1196167B1 (en) | 1999-07-02 | 2006-04-19 | Stuart A. Lipton | Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions |
| GB9919843D0 (en) | 1999-08-20 | 1999-10-27 | Smithkline Beecham Plc | Novel compounds |
| DE19948417A1 (de) | 1999-10-07 | 2001-04-19 | Morphochem Ag | Imidazol-Derivate und ihre Verwendung als Arzneimittel |
| CA2396693A1 (en) | 1999-12-28 | 2001-07-05 | Stephen T. Wrobleski | Cytokine, especially tnf-alpha, inhibitors |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
| US7041277B2 (en) | 2000-03-10 | 2006-05-09 | Cadbury Adams Usa Llc | Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same |
| CA2308994A1 (en) | 2000-05-19 | 2001-11-19 | Aegera Therapeutics Inc. | Neuroprotective compounds |
| AU2001284823B2 (en) | 2000-08-14 | 2006-11-30 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
| MXPA03001962A (es) | 2000-09-06 | 2004-03-26 | Johnson & Johnson | Metodo para tratar alergias utilizando pirazoles sustituidos. |
| CN1642973A (zh) | 2000-09-06 | 2005-07-20 | 奥索-麦克尼尔药品公司 | 治疗变态反应的方法 |
| AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| AU2001294518A1 (en) | 2000-09-22 | 2002-04-02 | Eli Lilly And Company | Stereoselective process for preparing cyclohexyl amine derivatives |
| DK1355904T3 (da) | 2000-12-22 | 2007-10-15 | Wyeth Corp | Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander |
| JP4343534B2 (ja) | 2001-03-02 | 2009-10-14 | ゲーペーツェー バイオテック アクチェンゲゼルシャフト | ３ハイブリッド・アッセイ・システム |
| WO2002072587A1 (en) | 2001-03-14 | 2002-09-19 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| WO2002085896A1 (en) | 2001-04-24 | 2002-10-31 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan |
| US6656950B2 (en) | 2001-04-25 | 2003-12-02 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine |
| CA2445543A1 (en) | 2001-04-26 | 2002-11-07 | Hong Gao | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-¬1,4|-benzodioxans |
| US6593350B2 (en) | 2001-04-26 | 2003-07-15 | Wyeth | Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole |
| US6656947B2 (en) | 2001-04-26 | 2003-12-02 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline |
| EP1381614B1 (en) | 2001-04-26 | 2006-08-02 | Wyeth | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO¬2,3-f|QUINOXALINE |
| ES2247327T3 (es) | 2001-04-26 | 2006-03-01 | Wyeth | Derivados azaheterociclimetilicos antidepresivos (isrs) de 7,8-dihidro-3h-6,9-dioxa-1,3-diazaciclopenta(a) naftaleno. |
| EP1392700B1 (en) | 2001-04-30 | 2004-09-29 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta(a)naphthalene |
| US6555560B2 (en) | 2001-04-30 | 2003-04-29 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene |
| GB0111186D0 (en) | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
| AU2002309769B2 (en) | 2001-05-17 | 2008-04-17 | Wyeth | Processes for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino-[2,3-f] quinoline |
| US6825190B2 (en) | 2001-06-15 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| US6903110B2 (en) | 2001-07-25 | 2005-06-07 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene |
| CN100434079C (zh) | 2001-08-14 | 2008-11-19 | 富山化学工业株式会社 | 吡嗪核苷酸/吡嗪核苷类似物及其医药用途 |
| US20040236110A1 (en) | 2001-09-26 | 2004-11-25 | Ladouceur Gaetan H | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| WO2003031439A1 (en) | 2001-10-05 | 2003-04-17 | Wyeth | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole |
| US7361671B2 (en) | 2001-11-15 | 2008-04-22 | The Institute For Pharmaceutical Discovery, Inc. | Substituted heteroarylalkanoic acids |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| EP1501833B1 (en) | 2002-04-26 | 2005-11-02 | Pfizer Products Inc. | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| US7429609B2 (en) | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
| PT1532145E (pt) | 2002-08-02 | 2007-01-31 | Vertex Pharma | Composiçoes de pirazole úteis como inibidores de gsk-3 |
| AU2002368154A1 (en) | 2002-08-08 | 2004-02-25 | Ribapharm Inc. | Improved synthesis for hydroxyalkylated heterocyclic bases |
| SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| MXPA05009068A (es) | 2003-02-26 | 2005-10-19 | Boehringer Ingelheim Pharma | Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos. |
| JP4787150B2 (ja) | 2003-03-06 | 2011-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｊｎｋ阻害剤 |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| WO2005000813A1 (en) | 2003-05-30 | 2005-01-06 | Imclone Systems Incorporated | Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors |
| WO2004106298A1 (en) | 2003-05-30 | 2004-12-09 | Janssen Pharmaceutica N.V. | Indole derivatives with an improved antipsychotic activity |
| JP2007526894A (ja) | 2003-07-16 | 2007-09-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グリコーゲンシンターゼキナーゼ３インヒビターとしてのトリアゾロピリミジン誘導体 |
| AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| CA2540828A1 (en) | 2003-09-30 | 2005-04-14 | Scios Inc. | Heterocyclic amides and sulfonamides |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
| GB0405055D0 (en) | 2004-03-05 | 2004-04-07 | Eisai London Res Lab Ltd | JNK inhibitors |
| CA2560454C (en) | 2004-03-30 | 2013-05-21 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
| EP1756108A2 (en) | 2004-04-02 | 2007-02-28 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
| ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| KR100476851B1 (ko) | 2004-05-18 | 2005-03-17 | (주)성신엔지니어링 | 중력식 섬유여과기 |
| US20060058339A1 (en) | 2004-06-17 | 2006-03-16 | Ibrahim Prabha N | Compounds modulating c-kit activity and uses therefor |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| US20060122213A1 (en) | 2004-06-30 | 2006-06-08 | Francoise Pierard | Azaindoles useful as inhibitors of protein kinases |
| WO2006015123A1 (en) | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP2439207A1 (en) | 2004-10-04 | 2012-04-11 | Millennium Pharmaceuticals, Inc. | Lactam Compounds Useful as Protein Kinase Inhibitors |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| US7528138B2 (en) | 2004-11-04 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
| US20060122185A1 (en) | 2004-11-22 | 2006-06-08 | Jeremy Green | Bicyclic inhibitors of Rho kinase |
| EP2486942B1 (en) | 2004-11-24 | 2018-10-10 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| EP1828180A4 (en) | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| WO2006065946A1 (en) | 2004-12-16 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
| US20060161001A1 (en) | 2004-12-20 | 2006-07-20 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| ES2320487T3 (es) | 2005-02-03 | 2009-05-22 | Vertex Pharmaceuticals, Inc. | Pirrolopirimidinas utiles como inhibidores de proteina quinasas. |
| BRPI0610828A2 (pt) | 2005-05-16 | 2010-07-27 | Irm Llc | compostos e composições como inibidores de proteìna quinase |
| ES2380795T3 (es) | 2005-05-20 | 2012-05-18 | Vertex Pharmaceuticals, Inc. | Pirrolopiridinas útiles como inhibidores de proteínas quinasas |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| EP1749523A1 (en) | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | GSK-3 inhibitors |
| GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
| ES2401192T3 (es) | 2005-09-30 | 2013-04-17 | Vertex Pharmceuticals Incorporated | Deazapurinas útiles como inhibidores de janus cinasas |
| US20130096302A1 (en) | 2005-11-22 | 2013-04-18 | Hayley Binch | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| CN101374839A (zh) * | 2006-01-17 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| EP2537849A3 (en) | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| KR20080095902A (ko) | 2006-02-14 | 2008-10-29 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀 |
| US7659283B2 (en) | 2006-02-14 | 2010-02-09 | Vertex Pharmaceuticals Incorporated | Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases |
| DE102006012617A1 (de) | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| RU2008143361A (ru) | 2006-04-05 | 2010-05-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Деазапурины в качестве ингибиторов янус-киназ |
| CA2650196A1 (en) * | 2006-04-26 | 2007-11-01 | Stewart James Baker | Pyrimidine derivatives as pi3k inhibitors |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| WO2007146057A2 (en) | 2006-06-09 | 2007-12-21 | Wisconsin Alumni Research Foundation | Screening method for modulators of viral transcription or replication |
| EP2038272B8 (en) | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| ES2657635T3 (es) | 2006-08-08 | 2018-03-06 | Chugai Seiyaku Kabushiki Kaisha | Derivado de pirimidina como inhibidor de PI3K y uso del mismo |
| AU2007287428B2 (en) * | 2006-08-24 | 2011-08-11 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| CA2672612A1 (en) | 2006-12-14 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as protein kinase inhibitors |
| NZ577798A (en) | 2006-12-21 | 2012-04-27 | Vertex Pharma | 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| TW200840581A (en) | 2007-02-28 | 2008-10-16 | Astrazeneca Ab | Novel pyrimidine derivatives |
| EP2134709A1 (en) | 2007-03-09 | 2009-12-23 | Vertex Pharmaceuticals, Inc. | Aminopyridines useful as inhibitors of protein kinases |
| NZ579485A (en) | 2007-03-09 | 2012-02-24 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
| MX2009009590A (es) | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
| PT2139892E (pt) | 2007-03-22 | 2011-11-21 | Takeda Pharmaceutical | Pirimidodiazepinas substituídas úteis como inibidores da plk1 |
| KR20090130105A (ko) | 2007-04-05 | 2009-12-17 | 알라 캠, 엘엘씨 | 치환된 2,3,4,5-테트라히드로-1ｈ-피리도［4,3-ｂ］ 인돌, 그 제조방법 및 용도 |
| RU2339637C1 (ru) | 2007-04-05 | 2008-11-27 | Андрей Александрович Иващенко | Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием |
| EP2190849B1 (en) | 2007-08-15 | 2013-11-20 | Vertex Pharmceuticals Incorporated | 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases |
| EP2610256B1 (en) | 2007-09-28 | 2016-04-27 | Cyclacel Limited | Pyrimidine derivatives as protein kinase inhibitors |
| SG185289A1 (en) | 2007-10-09 | 2012-11-29 | European Molecular Biology Lab Embl | Soluble fragments of influenza virus pb2 protein capable of binding rna-cap |
| KR20100093552A (ko) | 2007-11-02 | 2010-08-25 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 ｃ-세타로서의 [1ｈ-피라졸로[3,4-ｂ]피리딘-4-일]-페닐 또는 -피리딘-2-일 유도체 |
| PT2463282E (pt) | 2007-11-05 | 2013-11-11 | Novartis Ag | Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose |
| RU2503676C2 (ru) | 2008-02-25 | 2014-01-10 | Ф.Хоффманн-Ля Рош Аг | Пирролопиразиновые ингибиторы киназы |
| WO2009145814A2 (en) | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
| WO2009125395A1 (en) | 2008-04-09 | 2009-10-15 | Technion Research & Development Foundation Ltd. | Anti influenza antibodies and uses thereof |
| EP2356122B1 (en) | 2008-06-23 | 2019-03-20 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors |
| AU2009271663B2 (en) | 2008-06-23 | 2014-04-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors |
| US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| JP2011529062A (ja) | 2008-07-23 | 2011-12-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾロピリジンキナーゼ阻害剤 |
| WO2010011768A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| CA2731496A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| EP2427464A1 (en) | 2009-05-06 | 2012-03-14 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines |
| WO2010143207A1 (en) | 2009-06-11 | 2010-12-16 | Rubicon Research Private Limited | Taste-masked oral formulations of influenza antivirals |
| GEP20207129B (en) | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| WO2011008915A1 (en) | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyridine inhibitors of kinases |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| ME02446B (me) | 2010-04-07 | 2016-09-20 | Vertex Pharma | Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline |
| KR20130094710A (ko) | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 |
| WO2011137022A1 (en) | 2010-04-27 | 2011-11-03 | Merck Sharp & Dohme Corp. | Azaindoles as janus kinase inhibitors |
| CA2822059A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| CN103492381A (zh) | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | 流感病毒复制的抑制剂 |
| WO2012083122A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceutical Incorporated | Inhibitors of influenza viruses replication |
| EP2729465A2 (en) | 2011-07-05 | 2014-05-14 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for producing azaindoles |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| AU2012336019A1 (en) | 2011-11-07 | 2014-05-29 | Vertex Pharmaceuticals Incorporated | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
| WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| WO2014201332A1 (en) | 2013-06-14 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical combinations useful for treating rheumatoid arthritis |
| RU2016110094A (ru) | 2013-08-22 | 2017-09-27 | Вертекс Фармасьютикалз Инкорпорейтед | Изотопно-обогащенные азаиндолы |
| KR102323515B1 (ko) | 2013-09-12 | 2021-11-05 | 얀센 바이오파마, 인코퍼레이트. | 아자-피리돈 화합물 및 이의 용도 |
| US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
| MX2016006197A (es) | 2013-11-13 | 2016-08-08 | Vertex Pharma | Formulaciones de compuestos de azaindol. |
| EP3421468B1 (en) | 2013-11-13 | 2020-11-04 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| HRP20191525T1 (hr) | 2013-11-13 | 2019-11-29 | Vertex Pharma | Inhibitori replikacije virusa influence |
| JP6577570B2 (ja) | 2014-08-08 | 2019-09-18 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | インフルエンザウイルス感染に使用するためのインドール類 |
| DK3191489T3 (da) | 2014-09-08 | 2021-03-29 | Janssen Sciences Ireland Unlimited Co | Pyrrolopyrimidiner til anvendelse ved influenzavirusinfektion |
| MA40772A (fr) | 2014-10-02 | 2017-08-08 | Vertex Pharma | Variants du virus de la grippe a |
| MA40773A (fr) | 2014-10-02 | 2017-08-08 | Vertex Pharma | Variants du virus influenza a |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| MA43298A (fr) | 2015-11-27 | 2021-04-14 | Janssen Sciences Ireland Unlimited Co | Derives heterocycliques d'indole pour des infections par le virus de la influenza |
| EA201891576A1 (ru) | 2016-01-07 | 2018-11-30 | Янссен Сайенсиз Айрлэнд Юси | Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа |
| KR20180100375A (ko) | 2016-01-20 | 2018-09-10 | 얀센 사이언시즈 아일랜드 유씨 | 인플루엔자 바이러스 감염에서 사용하기 위한 아릴 치환 피리미딘 |
| WO2017223231A1 (en) | 2016-06-21 | 2017-12-28 | Alios Biopharma, Inc. | (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza |
| EP3609502A1 (en) | 2017-04-12 | 2020-02-19 | Vertex Pharmaceuticals Incorporated | Combination therapies for treating influenza virus infection |
-
2010
- 2010-06-17 GE GEAP201013375A patent/GEP20207129B/en unknown
- 2010-06-17 AR ARP100102150A patent/AR077130A1/es not_active Application Discontinuation
- 2010-06-17 GE GEAP201012538A patent/GEP20156325B/en unknown
- 2010-06-17 SI SI201031307A patent/SI2442809T1/sl unknown
- 2010-06-17 PT PT107267601T patent/PT2442809T/pt unknown
- 2010-06-17 SI SI201031779T patent/SI3141252T1/sl unknown
- 2010-06-17 MX MX2015000091A patent/MX348066B/es unknown
- 2010-06-17 TW TW105139121A patent/TWI639596B/zh not_active IP Right Cessation
- 2010-06-17 CN CN201910673938.2A patent/CN110540538A/zh active Pending
- 2010-06-17 WO PCT/US2010/038988 patent/WO2010148197A1/en not_active Ceased
- 2010-06-17 NZ NZ619259A patent/NZ619259A/en not_active IP Right Cessation
- 2010-06-17 PL PL16181549T patent/PL3141252T3/pl unknown
- 2010-06-17 SG SG10201405826RA patent/SG10201405826RA/en unknown
- 2010-06-17 EP EP18177481.1A patent/EP3427738B1/en not_active Not-in-force
- 2010-06-17 EP EP10726760.1A patent/EP2442809B1/en active Active
- 2010-06-17 PE PE2015002683A patent/PE20160127A1/es unknown
- 2010-06-17 AU AU2010262905A patent/AU2010262905B2/en not_active Ceased
- 2010-06-17 TW TW099119816A patent/TWI483941B/zh not_active IP Right Cessation
- 2010-06-17 PL PL10726760T patent/PL2442809T3/pl unknown
- 2010-06-17 DK DK10726760.1T patent/DK2442809T3/en active
- 2010-06-17 EA EA201500871A patent/EA037529B1/ru not_active IP Right Cessation
- 2010-06-17 EA EA201500266A patent/EA030188B1/ru unknown
- 2010-06-17 TR TR2018/15272T patent/TR201815272T4/tr unknown
- 2010-06-17 MX MX2017006441A patent/MX375432B/es unknown
- 2010-06-17 BR BRPI1011993-0A patent/BRPI1011993A2/pt active Search and Examination
- 2010-06-17 JP JP2012516299A patent/JP5721706B2/ja not_active Expired - Fee Related
- 2010-06-17 TW TW107126935A patent/TWI666209B/zh not_active IP Right Cessation
- 2010-06-17 ME MEP-2016-272A patent/ME02558B/me unknown
- 2010-06-17 UY UY0001032717A patent/UY32717A/es active IP Right Grant
- 2010-06-17 PH PH1/2015/501678A patent/PH12015501678B1/en unknown
- 2010-06-17 CN CN201080036505.3A patent/CN102458408B/zh not_active Expired - Fee Related
- 2010-06-17 RS RS20181199A patent/RS57869B1/sr unknown
- 2010-06-17 CN CN201410195237.XA patent/CN104151312B/zh not_active Expired - Fee Related
- 2010-06-17 LT LTEP10726760.1T patent/LT2442809T/lt unknown
- 2010-06-17 CN CN201510221329.5A patent/CN104940202B/zh not_active Expired - Fee Related
- 2010-06-17 HR HRP20161577TT patent/HRP20161577T1/hr unknown
- 2010-06-17 SG SG2011090651A patent/SG176722A1/en unknown
- 2010-06-17 NZ NZ597059A patent/NZ597059A/en not_active IP Right Cessation
- 2010-06-17 DK DK16181549.3T patent/DK3141252T3/en active
- 2010-06-17 RS RS20161032A patent/RS55341B1/sr unknown
- 2010-06-17 GE GEAP201013376A patent/GEP20227397B/en unknown
- 2010-06-17 PE PE2011002120A patent/PE20120508A1/es active IP Right Grant
- 2010-06-17 SG SG10201405827PA patent/SG10201405827PA/en unknown
- 2010-06-17 CA CA2764177A patent/CA2764177C/en not_active Expired - Fee Related
- 2010-06-17 KR KR1020127001354A patent/KR101702609B1/ko not_active Expired - Fee Related
- 2010-06-17 ES ES10726760.1T patent/ES2604667T3/es active Active
- 2010-06-17 PT PT16181549T patent/PT3141252T/pt unknown
- 2010-06-17 EP EP16181549.3A patent/EP3141252B8/en active Active
- 2010-06-17 LT LTEP16181549.3T patent/LT3141252T/lt unknown
- 2010-06-17 ES ES16181549.3T patent/ES2692396T3/es active Active
- 2010-06-17 KR KR1020177002581A patent/KR101903354B1/ko not_active Expired - Fee Related
- 2010-06-17 MX MX2011013475A patent/MX2011013475A/es active IP Right Grant
- 2010-06-17 CN CN201510221305.XA patent/CN104922128B/zh not_active Expired - Fee Related
- 2010-06-17 EA EA201270032A patent/EA025276B1/ru unknown
- 2010-06-17 HU HUE10726760A patent/HUE031048T2/en unknown
- 2010-06-17 KR KR1020187027093A patent/KR102050712B1/ko not_active Expired - Fee Related
- 2010-06-17 TW TW104103498A patent/TWI574963B/zh not_active IP Right Cessation
- 2010-06-17 AP AP2012006067A patent/AP3631A/xx active
-
2011
- 2011-12-12 ZA ZA2011/09127A patent/ZA201109127B/en unknown
- 2011-12-14 IL IL216980A patent/IL216980B/en active IP Right Grant
- 2011-12-15 US US13/327,206 patent/US20120171245A1/en not_active Abandoned
- 2011-12-16 CL CL2011003192A patent/CL2011003192A1/es unknown
-
2012
- 2012-01-17 CO CO12006237A patent/CO6491048A2/es active IP Right Grant
- 2012-01-17 EC EC2012011610A patent/ECSP12011610A/es unknown
-
2013
- 2013-12-06 US US14/098,867 patent/US8829007B2/en active Active
-
2014
- 2014-06-16 US US14/305,393 patent/US9345708B2/en active Active
- 2014-11-13 JP JP2014230557A patent/JP2015034177A/ja not_active Withdrawn
- 2014-11-13 JP JP2014230556A patent/JP6030619B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-04 ZA ZA2015/00820A patent/ZA201500820B/en unknown
- 2015-11-02 US US14/929,634 patent/US9518056B2/en active Active
-
2016
- 2016-09-06 JP JP2016173354A patent/JP6348939B2/ja not_active Expired - Fee Related
- 2016-10-21 US US15/299,757 patent/US9808459B2/en active Active
- 2016-11-21 CY CY20161101196T patent/CY1118246T1/el unknown
-
2017
- 2017-09-28 US US15/718,186 patent/US10039762B2/en active Active
- 2017-10-17 JP JP2017200914A patent/JP6620135B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-25 US US16/016,917 patent/US10874673B2/en active Active
- 2018-10-19 HR HRP20181715TT patent/HRP20181715T1/hr unknown
- 2018-10-31 CY CY181101086T patent/CY1120778T1/el unknown
- 2018-11-01 IL IL262734A patent/IL262734B/en active IP Right Grant
-
2019
- 2019-10-01 JP JP2019181224A patent/JP2020011990A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011993A2 (pt) | inibidores de replicação do vírus influenza, seu uso, método de preparação dos mesmos e compositção farmacêutica que os compreende | |
| AU2018200219B2 (en) | Inhibitors of Influenza Viruses Replication | |
| AU2015203600B2 (en) | Inhibitors of Influenza Viruses Replication | |
| OA16260A (en) | Inhibitors of influenza viruses replication. | |
| HK1235283B (en) | Inhibitors of influenza viruses replication | |
| HK40003103A (en) | Inhibitors of influenza viruses replication | |
| HK1235283A (en) | Inhibitors of influenza viruses replication | |
| HK1235283A1 (en) | Inhibitors of influenza viruses replication | |
| HK1169310B (en) | Inhibitors of influenza viruses replication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA. |
|
| B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: PETICAO NO 860140069811 DE 12/05/2014 NAO CONHECIDA POR FALTA DE ENVIO DE DOCUMENTACAO COMPROBATORIA PARA INCLUSAO DOS INVENTORES FRANCESCO G. SALITURO E ANN DAK-YEE KWONG. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |